About this trial
Patients with type III glycogen storage disease (GSDIII) can develop liver fibrosis, which can be complicated by liver failure or even hepatocellular carcinoma. Since the beginning of the 21st century, non-invasive techniques for assessing fibrosis, such as liver elastography, have been developed. These techniques often make it possible to avoid liver biopsies during patient follow-up and have already been validated in the management of several diseases in adults. These techniques are also beginning to be recommended for monitoring certain chronic liver diseases in children.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Minors: from birth to 17 years
Adults: 18 to 21 years
Subjects being monitored for type III glycogen storage disease and having had at least one liver elastography measurement during their follow-up.
Disqualifiers
None
Trial population
Patients under 22 years of age
Trial design
Cohort
Retrospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Liver elastography values
Liver fibrosis is classified into four stages, from 0 to 4: * F0 corresponds to the absence of fibrosis * F4 corresponds to established cirrhosis.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.